Cancer broncho-pulmonaire : quel bilan moléculaire ?

Abstract

The identification of targetable molecular alterations is now required before starting any treatment of patients with non-small cell lung cancer, particularly for non-squamous. Molecular diagnosis is mainly realized on tissue samples but analyzing circulating tumor DNA is also a valuable tool in the daily practice. The diversification of therapeutic targets requires the use of various molecular biology techniques adapted to the search for targets on DNA (point mutations, small deletions / insertions, gene amplification) but also on RNA (fusion transcript, exon skipping). In addition to next generation sequencing, many targeted techniques are also proposed by laboratories. The choice of technologies must be made according to the criteria of exhaustiveness of the results, analytical sensitivity, delay of results and cost. For this, a close discussion with clinicians and pathologists is essential.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.